Longeveron Announces Two Abstracts Accepted for Presentation at the Gerontological Society of America 2021 Annual Scientific Meeting
Longeveron Inc. (NASDAQ: LGVN) announced that two abstracts for its investigational cell therapy, Lomecel-B, have been accepted for presentation at the Gerontological Society of America (GSA) 2021 Annual Scientific Meeting, scheduled for November 10-14, 2021, in Phoenix, AZ. The abstracts include:
- A Phase 2b Clinical Trial Assessing Lomecel-B Infusion in Individuals with Aging Frailty
- A Phase 1 Trial Assessing Lomecel-B Infusion in Individuals with Alzheimer’s Disease
This indicates ongoing progress in clinical trials aimed at addressing aging-related conditions.
- Acceptance of two abstracts for Lomecel-B at a prominent scientific meeting indicates credibility and potential interest in the therapy.
- Lomecel-B targets serious aging-related conditions, potentially addressing significant market needs.
- None.
MIAMI, June 30, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, today announced that two abstracts for Lomecel-B, the Company’s investigational cell therapy being developed to treat aging-related life-threatening conditions, have been accepted for poster presentation at the Gerontological Society of America (GSA) 2021 Annual Scientific Meeting, being held November 10-14, 2021 in Phoenix, AZ. The full abstracts, including the dates and times of presentations, will be provided closer to the meeting once the GSA has provided these details to Longeveron. The titles of the presentations are as follows:
Title: A Phase 2b Clinical Trial Assessing Lomecel-B Infusion in Individuals with Aging Frailty: Study Design and Rationale.
Abstract ID: 1027576
Title: A Phase 1 Trial Assessing Lomecel-B Infusion in Individuals with Alzheimer’s Disease: Study Design and Rationale
Abstract ID: 1028352
Additional meeting information can be found on the GSA Annual Scientific Meeting website at www.gsa2021.org. Once published, the presented posters will also be available under “Events & Presentations” in the Investors section of the Company’s website at investors.longeveron.com.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Additional information about the Company is available at www.longeveron.com.
Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements that reflect management's current expectations, assumptions, and estimates of future performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as "believe," "expects," "may," "looks to," "will," "should," "plan," "intend," "on condition," "target," "see," "potential," "estimates," "preliminary," or "anticipates" or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Moreover, forward-looking statements in this release include, but are not limited to, statements about the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials; the size of the market opportunity for our product candidates, the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our ability to obtain and maintain regulatory approval of our product candidates, our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others. Further information relating to factors that may impact the Company's results and forward-looking statements are disclosed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investor Contact:
Brendan Payne
Stern Investor Relations
Office Direct: 212-698-8695 |Office Main: 212-362-1200
brendan.payne@sternir.com | www.sternir.com
Source: Longeveron Inc
Source: LGVN
FAQ
What is Lomecel-B and its significance for LGVN?
When will the GSA Annual Scientific Meeting take place?
What two clinical trials are being presented for Lomecel-B?
